Cytosorbents (NASDAQ:CTSO) issued its earnings results on Tuesday. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08), Fidelity Earnings reports. Cytosorbents had a negative return on equity of 105.97% and a negative net margin of 72.43%. The firm had revenue of $6.10 million for the quarter, compared to analysts’ expectations of $6.49 million.
Shares of Cytosorbents stock traded down $0.15 on Thursday, reaching $4.57. The company had a trading volume of 2,234 shares, compared to its average volume of 119,553. The firm’s 50 day moving average price is $4.92 and its two-hundred day moving average price is $5.94. The firm has a market cap of $163.13 million, a PE ratio of -8.16 and a beta of 1.68. Cytosorbents has a 52-week low of $3.68 and a 52-week high of $12.00. The company has a debt-to-equity ratio of 0.87, a quick ratio of 3.00 and a current ratio of 3.21.
CTSO has been the topic of a number of analyst reports. B. Riley set a $10.00 target price on shares of Cytosorbents and gave the stock a “buy” rating in a research note on Monday, October 21st. Maxim Group set a $14.00 target price on shares of Cytosorbents and gave the stock a “buy” rating in a research note on Wednesday, August 7th. ValuEngine downgraded shares of Cytosorbents from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Cytosorbents in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Cytosorbents currently has an average rating of “Hold” and an average price target of $13.00.
In related news, CFO Kathleen P. Bloch purchased 6,500 shares of Cytosorbents stock in a transaction dated Friday, August 16th. The shares were acquired at an average cost of $4.83 per share, with a total value of $31,395.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 5.60% of the stock is currently owned by insiders.
Cytosorbents Company Profile
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Further Reading: Most Volatile Stocks – What Investors Need to Know to Maximize ROI
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.